DEF 14A: CV Sciences Sets Date for Annual Stockholders Meeting, Outlines Key Proposals

Sentiment:

Proxy Statement 11 April 2024 8:16 PM

CV Sciences will hold its annual stockholders meeting virtually on June 3, 2024, to vote on director elections, auditor ratification, and executive compensation.

Summary

CV Sciences, Inc. will hold its annual meeting of stockholders on June 3, 2024, at 10:00 a.m. Pacific Time, in a virtual format.
Stockholders of record as of April 5, 2024, are entitled to vote.
The meeting's agenda includes the election of three directors, ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and a non-binding advisory vote on named executive officer compensation.
The Board of Directors recommends voting FOR the election of each director nominee and FOR the ratification of the auditor and the advisory vote on executive compensation.
Proxy materials are primarily available electronically, with a Notice of Internet Availability mailed to stockholders on or about April 11, 2024.
At the close of business on the Record Date, 163,228,469 shares of the Company's common stock were issued and outstanding.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining standard corporate governance procedures and board recommendations. There are no major red flags or concerns raised.

Positives

The Board is actively seeking stockholder input on key decisions.
The company is providing detailed information on director nominees and their qualifications.
The virtual meeting format aims to provide a convenient experience for all stockholders.
The company is committed to corporate governance best practices, including seeking ratification of the independent auditor.

Negatives

Due to the Company's financial performance for fiscal years 2023 and 2022, no cash incentive bonus was earned by or paid to our executive officers.
The company has deferred a portion of our executive cash compensation earned prior to September 30, 2022.

Risks

Failure to achieve a quorum at the meeting could necessitate adjournment.
Negative voting results on executive compensation could impact future compensation decisions.
Changes in the independent registered public accounting firm could disrupt financial reporting.
Conflicts of interest may arise for directors and officers due to their involvement in other businesses.

Future Outlook

The Board intends to consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Management Comments

Our Board of Directors has carefully reviewed and considered the foregoing proposals and has concluded that each proposal is in the best interests of the Company and its stockholders.
Therefore, our Board of Directors has approved each proposal and recommends that you vote FOR each of the director nominees included in Proposal 1 and FOR all of the other foregoing proposals.

Industry Context

The cannabis industry is rapidly evolving, and CV Sciences' corporate governance practices are essential for maintaining investor confidence and navigating regulatory complexities.

Comparison to Industry Standards

Many companies listed on major exchanges are required to have a majority of independent directors, which CV Sciences aims to meet despite its OTC:QB listing.
The company's approach to executive compensation and equity incentive plans is consistent with practices in the broader consumer products and pharmaceutical industries.
Peer companies such as Charlotte's Web Holdings and cbdMD also hold annual meetings and solicit proxies for key corporate governance matters.

Stakeholder Impact

Shareholders will have the opportunity to influence key decisions through their votes.
Employees' compensation and benefits are indirectly affected by the advisory vote on executive compensation.
The selection of the independent auditor impacts the reliability of financial reporting.

Next Steps

Stockholders should review the proxy materials and vote on the proposals.
The company will announce preliminary voting results at the meeting and publish final results in a Form 8-K.

Key Dates

Date	Description
August 25, 2014	Joseph Dowling appointed Secretary
July 23, 2014	Company stockholders approved the Company's 2013 Equity Incentive Plan
December 21, 2015	Company stockholders approved an amendment to the 2013 Plan to increase the number of shares that may be issued under the 2013 Plan.
July 6, 2016	The Compensation Committee approved the grant of 6,000,000 standalone stock options to Mr. Mona, which were not granted under the 2013 Plan.
October 24, 2016	Company stockholders approved an amendment to the 2013 Plan to increase the number of shares that may be issued under the 2013 Plan.
March 15, 2017	The disinterested members of the Board approved the grant of 5,000,000 standalone stock options to Mr. Mona, Jr., which were not granted under the 2013 Plan.
July 14, 2017	Company stockholders approved an amendment to the 2013 Plan to increase the number of shares that may be issued under the 2013 Plan.
August 4, 2018	Company stockholders approved an amendment to the 2013 Plan to increase the number of shares that may be issued under the 2013 Plan.
May 31, 2018	Joseph Dowling appointed as our Chief Executive Officer (CEO)
June 11, 2019	Company stockholders approved an amendment to the 2013 Plan to increase the number of shares that may be issued under the 2013 Plan.
March 15, 2019	Joerg Grasser was appointed as the Chief Financial Officer of the Company.
July 21, 2022	Dr. Jamie Corroon was appointed to our Board of Directors
October 21, 2022	Mr. McCorkle was appointed to our Board of Directors
June 1, 2023	The 2013 Plan terminated and was replaced by the 2023 Plan
April 5, 2024	Record date for determining stockholders entitled to notice of, and to vote at, the Meeting.
April 11, 2024	Mailing date of the Notice of Internet Availability of Proxy Materials.
June 3, 2024	Date of the Annual Meeting of Stockholders.

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, auditor ratification, corporate governance, CV Sciences

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.